The present application belongs to the field of biological
medicine, and particularly relates to the use of ribo-
adenosine in the preparation of a
medicine for treating
fatty liver and reducing
obesity. The present application finds and confirms, through
cell experiments,
organoid experiments and animal experiments, that ribo-
adenosine can reduce
lipid accumulation, reduce
body weight and thus reduce
obesity, and can prevent and improve metabolic diseases related to
obesity; in particular, the present application finds that ribo-
adenosine can inhibit the synthesis of fatty acids and
cholesterol in liver cells, reduce the levels of fatty acids, triglycerides and
free cholesterol, improve
liver function, reduce
liver damage, and play a preventive and therapeutic role in metabolic
fatty liver.